News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Giulio Draetta: Tremendously proud of Tina Cascone for her presentation at the 2023 ESMO meeting presidential session
Photo of Tina Cascone from Giulio Draetta/Twitter
Oct 22, 2023, 17:22

Giulio Draetta: Tremendously proud of Tina Cascone for her presentation at the 2023 ESMO meeting presidential session

Giulio Draetta, Chief Scientific Officer at The University of Texas M.D. Anderson Cancer Center, shared on Twitter:

“Tremendously proud of Tina Cascone for her presentation at the 2023 ESMO meeting presidential session on the impact of neoadjuvant NIVO/chemo in respectable NSCLC.”

Source: Giulio Draetta/Twitter

cancer ESMO2023 Giulio Draetta NSCLC OncoDaily Oncology Tina Cascone
Special Coverage
Drugs
Jun 20, 2025, 02:19
Is Tamoxifen Chemotherapy? Understanding Its Role in Breast Cancer Treatment
Blog
Jun 19, 2025, 17:36
ESTRO Introduces KAYAC+ to Advance Radiation Therapy For Adolescents And Young Adults With Cancer
Blog
Jun 19, 2025, 17:26
XVII CCI LATAM Conference Was a Celebration Of a Growing Community, Unity, and Hope - Childhood Cancer International
Blog
Jun 19, 2025, 17:07
Join The AI For Everyone, Everywhere, Let’s talk about Large Language Models Meeting - SIOP
Blog
Jun 19, 2025, 16:57
David Planchard: We Need to Work Together to Develop The Wave of New Treatments That Is Coming For Our Patients
Blog
Jun 19, 2025, 16:21
Neeraj Agarwal: Poor Outcomes with SOC in mHSPC Prostate Cancer Patients With HRR Mutation
Blog
Jun 19, 2025, 16:12
World Kidney Cancer Day 2025: Uniting for Progress in the Fight Against Renal Cell Carcinoma
Blog
Jun 19, 2025, 16:01
IARC Marks World Kidney Cancer Day with New Video and Project Highlights
Science
Jun 19, 2025, 15:50
Alexey Kulikov Shared An Article on Cancer Vaccines and The Future of Immunotherapy
Opinion
Jun 19, 2025, 15:47
Mostafa Faisal: Primary Refractory AML and Allo-HCT - A 10-Year Retrospective Study from Japan
Blog
Jun 19, 2025, 15:36
Amol Akhade: KEYNOTE-689 - A Turning Point in Resectable HNSCC - Or a Cautious Step Forward?
Drugs
Jun 19, 2025, 15:30
Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma